Seek Returns logo

Command Palette

Search for a command to run...

ABBV vs. UNH: A Head-to-Head Stock Comparison

Here's a clear look at ABBV and UNH, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolABBVUNH
Company NameAbbVie Inc.UnitedHealth Group Incorporated
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesHealth Care Equipment & Services
GICS IndustryBiotechnologyHealth Care Providers & Services
GICS Sub-IndustryBiotechnologyManaged Health Care
Market Capitalization362.81 billion USD314.06 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateJanuary 2, 2013October 17, 1984
Security TypeCommon StockCommon Stock

ABBV's market capitalization stands at 362.81 billion USD, while UNH's is 314.06 billion USD, indicating their market valuations are broadly comparable.

Historical Performance

This chart compares the performance of ABBV and UNH by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. UNH: Growth of a $10,000 investment over the past five years.

Historical Performance at a Glance

SymbolABBVUNH
5-Day Price Return-1.58%10.18%
13-Week Price Return-4.31%4.53%
26-Week Price Return-10.48%-3.87%
52-Week Price Return20.55%-18.65%
Month-to-Date Return-5.69%27.87%
Year-to-Date Return-10.23%4.82%
10-Day Avg. Volume6.19M8.92M
3-Month Avg. Volume6.86M9.08M
3-Month Volatility24.99%53.52%
Beta0.300.55

UNH carries a higher beta at 0.55, indicating it's more sensitive to market moves, while ABBV (beta: 0.30) exhibits greater stability.

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry
Max
101.12%
Q3
10.39%
Median
-16.10%
Q1
-50.48%
Min
-131.19%

In the upper quartile for the Biotechnology industry, ABBV's Return on Equity of 95.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

UNH

12.50%

Health Care Providers & Services Industry
Max
27.53%
Q3
15.53%
Median
8.79%
Q1
6.65%
Min
-1.88%

UNH's Return on Equity of 12.50% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

ABBV vs. UNH: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.91%

Biotechnology Industry
Max
101.47%
Q3
21.88%
Median
-4.00%
Q1
-146.66%
Min
-310.18%

ABBV's Net Profit Margin of 6.91% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

UNH

2.69%

Health Care Providers & Services Industry
Max
11.23%
Q3
5.52%
Median
3.02%
Q1
1.10%
Min
-3.43%

UNH's Net Profit Margin of 2.69% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

ABBV vs. UNH: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Operating Profit Margin (TTM)

ABBV

24.65%

Biotechnology Industry
Max
75.52%
Q3
24.73%
Median
-0.52%
Q1
-160.14%
Min
-381.98%

ABBV's Operating Profit Margin of 24.65% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

UNH

4.18%

Health Care Providers & Services Industry
Max
18.14%
Q3
9.29%
Median
5.25%
Q1
2.05%
Min
-3.91%

UNH's Operating Profit Margin of 4.18% is around the midpoint for the Health Care Providers & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.

ABBV vs. UNH: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Profitability at a Glance

SymbolABBVUNH
Return on Equity (TTM)95.59%12.50%
Return on Assets (TTM)3.12%3.88%
Net Profit Margin (TTM)6.91%2.69%
Operating Profit Margin (TTM)24.65%4.18%
Gross Profit Margin (TTM)71.62%--

Financial Strength

Current Ratio (MRQ)

ABBV

0.67

Biotechnology Industry
Max
20.15
Q3
10.00
Median
4.41
Q1
2.57
Min
0.67

ABBV's Current Ratio of 0.67 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

UNH

0.95

Health Care Providers & Services Industry
Max
1.90
Q3
1.47
Median
1.24
Q1
0.97
Min
0.23

UNH's Current Ratio of 0.95 falls into the lower quartile for the Health Care Providers & Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

ABBV vs. UNH: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry
Max
1.49
Q3
0.66
Median
0.12
Q1
0.00
Min
0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

UNH

0.78

Health Care Providers & Services Industry
Max
2.35
Q3
1.29
Median
0.76
Q1
0.48
Min
0.00

UNH's Debt-to-Equity Ratio of 0.78 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ABBV vs. UNH: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

3.46

Biotechnology Industry
Max
72.37
Q3
2.99
Median
-7.31
Q1
-59.29
Min
-132.16

ABBV's Interest Coverage Ratio of 3.46 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

UNH

4.67

Health Care Providers & Services Industry
Max
17.70
Q3
8.70
Median
5.24
Q1
2.50
Min
-6.68

UNH's Interest Coverage Ratio of 4.67 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.

ABBV vs. UNH: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Financial Strength at a Glance

SymbolABBVUNH
Current Ratio (MRQ)0.670.95
Quick Ratio (MRQ)0.410.75
Debt-to-Equity Ratio (MRQ)49.220.78
Interest Coverage Ratio (TTM)3.464.67

Growth

Revenue Growth

ABBV vs. UNH: A comparison of their Revenue Growth across different time periods.

Revenue Growth at a Glance

SymbolABBVUNH
Revenue Growth (MRQ vs Prior YoY)10.04%12.31%
Revenue Growth (TTM vs Prior YoY)8.57%11.81%
3-Year Revenue CAGR1.75%11.35%
5-Year Revenue CAGR5.95%11.72%

EPS Growth

ABBV vs. UNH: A comparison of their EPS Growth across different time periods.

EPS Growth at a Glance

SymbolABBVUNH
EPS Growth (MRQ vs Prior YoY)---99.82%
EPS Growth (TTM vs Prior YoY)-1.30%-14.94%
3-Year EPS CAGR-28.99%-14.51%
5-Year EPS CAGR-2.88%-3.76%

Dividend

Dividend Yield (TTM)

ABBV

3.26%

Biotechnology Industry
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ABBV's Dividend Yield of 3.26% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend's sustainability.

UNH

2.48%

Health Care Providers & Services Industry
Max
5.25%
Q3
2.68%
Median
1.07%
Q1
0.00%
Min
0.00%

UNH's Dividend Yield of 2.48% is consistent with its peers in the Health Care Providers & Services industry, providing a dividend return that is standard for its sector.

ABBV vs. UNH: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

275.84%

Biotechnology Industry
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ABBV's Dividend Payout Ratio of 275.84% is above 100%. This means the company is paying out more in dividends than it earned, a practice that is often unsustainable and could indicate a risk to future dividend stability.

UNH

65.66%

Health Care Providers & Services Industry
Max
187.56%
Q3
76.84%
Median
29.78%
Q1
0.00%
Min
0.00%

UNH's Dividend Payout Ratio of 65.66% is within the typical range for the Health Care Providers & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

ABBV vs. UNH: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Dividend at a Glance

SymbolABBVUNH
Dividend Yield (TTM)3.26%2.48%
Dividend Payout Ratio (TTM)275.84%65.66%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

84.55

Biotechnology Industry
Max
55.06
Q3
36.18
Median
24.09
Q1
14.51
Min
3.28

At 84.55, ABBV's P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

UNH

26.48

Health Care Providers & Services Industry
Max
55.29
Q3
32.37
Median
21.01
Q1
13.45
Min
7.37

UNH's P/E Ratio of 26.48 is within the middle range for the Health Care Providers & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

ABBV vs. UNH: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

5.84

Biotechnology Industry
Max
56.62
Q3
31.07
Median
10.18
Q1
4.99
Min
0.78

ABBV's P/S Ratio of 5.84 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

UNH

0.71

Health Care Providers & Services Industry
Max
3.03
Q3
1.62
Median
0.76
Q1
0.28
Min
0.10

UNH's P/S Ratio of 0.71 aligns with the market consensus for the Health Care Providers & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ABBV vs. UNH: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry
Max
20.36
Q3
10.33
Median
5.13
Q1
3.08
Min
0.57

At 261.01, ABBV's P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market's valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

UNH

2.99

Health Care Providers & Services Industry
Max
9.26
Q3
5.43
Median
2.41
Q1
1.32
Min
0.63

UNH's P/B Ratio of 2.99 is within the conventional range for the Health Care Providers & Services industry. This shows a balanced market view, where the stock's price is neither at a significant premium nor a discount to the book value of its peers.

ABBV vs. UNH: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Valuation at a Glance

SymbolABBVUNH
Price-to-Earnings Ratio (TTM)84.5526.48
Price-to-Sales Ratio (TTM)5.840.71
Price-to-Book Ratio (MRQ)261.012.99
Price-to-Free Cash Flow Ratio (TTM)20.0518.37